亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Prospective Analysis of Arteriovenous Fistula Performance in the Context of Competing Risks

医学 背景(考古学) 动静脉瘘 血液透析 观察研究 前瞻性队列研究 外科 内科学 生物 古生物学
作者
Anukul Ghimire,Anita Lloyd,Susan K. Szigety,José Luis Merino,Karim Alibhai,Gerrit B. Winkelaar,Robert R. Quinn,Marcello Tonelli
出处
期刊:Kidney360 [American Society of Nephrology (ASN)]
标识
DOI:10.34067/kid.0000000650
摘要

Background: Many patients with newly created arteriovenous fistulas (AVF) may die before the AVF is needed for hemodialysis. However, formal competing risks frameworks are rarely used to report AVF patency, which may lead to biased estimates. We sought to identify the proportion of newly created AVF experiencing primary non-function and to describe long-term patency using a competing risk framework. Methods: We did a prospective observational study in 257 adults with newly created AVF in Alberta, Canada. The primary outcome was primary non-function. Secondary outcomes included loss of primary-patency, loss of assisted primary-patency, and loss of secondary functional-patency. Results were presented using icon-array plots to form the basis for future decision aids. Results: Participants were 63.0% male with mean age 62.3 years and median follow-up of 18.5 months (range 0.02-180 months). Of 257 participants, 50 could not be assessed for function or primary non-function, usually due to death. Of the remaining 207, 102 (49.3%) had primary non-function, and function was ultimately established for 142 (68.6%). Thus, only 142 of the 257 participants (55.3%) ultimately used the AVF for hemodialysis. High rates of competing risks led to biased results from Kaplan-Meier analyses of lost patency. When accounting for competing risks, loss of primary-patency among AVF with established function was 36.6%, 65.5% and 66.2%, at 1y, 3y and 5y respectively. Conclusions: Only 55% of fistulas were ultimately used for hemodialysis when accounting for competing risks and primary non-function. These results and the icon-array plots may inform discussions surrounding vascular access options for patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
23秒前
Criminology34应助科研通管家采纳,获得10
23秒前
搜集达人应助科研通管家采纳,获得10
23秒前
Achuia完成签到,获得积分10
1分钟前
1分钟前
程若男完成签到,获得积分10
2分钟前
小唐完成签到,获得积分10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
Criminology34应助科研通管家采纳,获得10
2分钟前
汉堡包应助Fairy采纳,获得10
2分钟前
量子星尘发布了新的文献求助10
2分钟前
Akim应助lngenuo采纳,获得30
3分钟前
3分钟前
3分钟前
3分钟前
Wei发布了新的文献求助10
3分钟前
3分钟前
Fairy发布了新的文献求助10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
4分钟前
Criminology34应助科研通管家采纳,获得10
4分钟前
科研通AI6应助科研通管家采纳,获得10
4分钟前
Criminology34应助科研通管家采纳,获得10
4分钟前
Criminology34应助科研通管家采纳,获得10
4分钟前
科研通AI6应助科研通管家采纳,获得10
4分钟前
4分钟前
hb完成签到,获得积分10
4分钟前
紫熊完成签到,获得积分10
5分钟前
啸西风完成签到,获得积分10
5分钟前
孙严青完成签到,获得积分10
5分钟前
Criminology34应助科研通管家采纳,获得10
6分钟前
科研通AI6应助科研通管家采纳,获得10
6分钟前
wanci应助野性的少司缘采纳,获得10
6分钟前
6分钟前
6分钟前
William完成签到 ,获得积分10
6分钟前
量子星尘发布了新的文献求助10
7分钟前
Criminology34应助Zhangfu采纳,获得20
7分钟前
Aixx完成签到 ,获得积分10
7分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Clinical Microbiology Procedures Handbook, Multi-Volume, 5th Edition 2000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1000
The Composition and Relative Chronology of Dynasties 16 and 17 in Egypt 1000
Russian Foreign Policy: Change and Continuity 800
Real World Research, 5th Edition 800
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5714938
求助须知:如何正确求助?哪些是违规求助? 5228707
关于积分的说明 15273909
捐赠科研通 4866079
什么是DOI,文献DOI怎么找? 2612676
邀请新用户注册赠送积分活动 1562848
关于科研通互助平台的介绍 1520139